The University of Zimbabwe-University of California, San Francisco Collaborative Research Programme (UZUCSF), in collaboration with the University of California, San Francisco (UCSF), is the site of a well-established, large Clinical Trials Unit (CTU) with 4 Clinical Research Sites (CRSs), covering 6 distinct geographic locations within and surrounding Harare, Zimbabwe. Experience gained from leadership and participation in 4 Division of AIDS (DAIDS) Networks (HPTN, MTN, ACTG, IMPAACT), positions the CTU to continue its contribution to the global understanding of HIV epidemiology and pathogenesis by serving as a center of research excellence in the prevention and control of HIV and AIDS. Utilizing the expertise of our international and local complement of investigators and highly trained and experienced research personnel, the CTU will accomplish this through completion of the following Specific Aims: 1.a. Identifying, screening, enrolling, and retaining existing and new at-risk populations in an environment of declining prevalence and incidence, in the following mission-specific domains of scientific priority of the 4 future NIAID-sponsored Networks: i) Adult HIV Therapeutic Strategies, including HIV cure, noninfectious comorbidities, and the infectious co-morbidities of hepatitis and tuberculosis; ii) Strategies to Address HIV and HIV-associated Infections in Pediatric and Maternal Populations; iii) Integrated HIV Prevention Strategies; and iv) Microbicide Strategies to Prevent HIV infections, and 1.b. Contributing to the scientific leadership of the 4 future NIAID-sponsored Networks. 2. Utilizing an increasingly efficient and sophisticated centralized administrative structure to support the uninterrupted execution of protocols across 4 restructured CRSs, laboratory, and pharmacy components. 3. Leveraging the integral relationships developed with the CTU's community partners and diverse stakeholders to disseminate research findings and translate research results into evidence-based best practices and policies at the local, regional, and international levels.

Public Health Relevance

The CTU's implementation of protocols across the 4 Networks may produce results that translate to policies within Zimbabwe and internationally to reduce HIV incidence and prevalence. The CTU anticipates that this new evidence will further inform policies to reduce the Zimbabwean HIV incidence from its current 3% to 2%; reduce current HIV prevalence from 13% to 7.5%; reduce HIV vertical transmission from the current 14% to <5%; and reduce TB incidence from 633 per 100,000 persons to 200 per 100,000.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1AI069436-11
Application #
9180667
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Germuga, Donna E
Project Start
2007-03-01
Project End
2020-11-30
Budget Start
2016-12-01
Budget End
2017-11-30
Support Year
11
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94118
Hosseinipour, Mina C; Kang, Minhee; Krown, Susan E et al. (2018) As-Needed Vs Immediate Etoposide Chemotherapy in Combination With Antiretroviral Therapy for Mild-to-Moderate AIDS-Associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. Clin Infect Dis 67:251-260
Torres, Thiago S; Harrison, Linda J; La Rosa, Alberto M et al. (2018) Quality of life among HIV-infected individuals failing first-line antiretroviral therapy in resource-limited settings. AIDS Care 30:954-962
Mhlanga, Felix G; Noguchi, Lisa; Balkus, Jennifer E et al. (2018) Implementation of a prospective pregnancy registry for antiretroviral based HIV prevention trials. HIV Clin Trials 19:8-14
Balkus, Jennifer E; Brown, Elizabeth R; Palanee-Phillips, Thesla et al. (2018) Performance of a Validated Risk Score to Predict HIV-1 Acquisition Among African Women Participating in a Trial of the Dapivirine Vaginal Ring. J Acquir Immune Defic Syndr 77:e8-e10
Musara, Petina; Montgomery, Elizabeth T; Mgodi, Nyaradzo M et al. (2018) How Presentation of Drug Detection Results Changed Reports of Product Adherence in South Africa, Uganda and Zimbabwe. AIDS Behav 22:877-886
Koay, Wei Li A; Lindsey, Jane C; Uprety, Priyanka et al. (2018) Intestinal Integrity Biomarkers in Early Antiretroviral-Treated Perinatally HIV-1-Infected Infants. J Infect Dis 218:1085-1089
Flynn, Patricia M; Taha, Taha E; Cababasay, Mae et al. (2018) Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomi J Acquir Immune Defic Syndr 77:383-392
Chernoff, Miriam C; Laughton, Barbara; Ratswana, Mmule et al. (2018) Validity of Neuropsychological Testing in Young African Children Affected by HIV. J Pediatr Infect Dis 13:185-201
Palumbo, Philip J; Fogel, Jessica M; Hudelson, Sarah E et al. (2018) HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052. J Acquir Immune Defic Syndr 77:484-491
Riddler, Sharon A; Husnik, Marla; Ramjee, Gita et al. (2017) HIV disease progression among women following seroconversion during a tenofovir-based HIV prevention trial. PLoS One 12:e0178594

Showing the most recent 10 out of 51 publications